Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B and C rounds bring $73mm to Apexigen

Executive Summary

Immuno-oncology firm Apexigen Inc. raised a total of $73mm through two venture rounds. It closed a $15mm Series B, led by Decheng Capital, and brought in $58mm through a Series C round led by 3E Bioventures Capital, Virtus Inspire Ventures, and SV Tech Ventures. (Decheng and 3E take board seats.) Proceeds will support R&D activities, including continued development of lead candidate APX005M, a Phase II monoclonal antibody targeting CD40 for multiple cancers.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies